Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2 Recruiting
65 enrolled
aCCeleR8-001
Phase 1/2 Recruiting
282 enrolled
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
SCOTI
Phase 2 Recruiting
50 enrolled
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Recruiting
308 enrolled
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
140 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 Recruiting
24 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 2/3 Recruiting
990 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/2 Recruiting
64 enrolled
TERTIO
Phase 2 Recruiting
105 enrolled
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Phase 3 Recruiting
700 enrolled
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Phase 2/3 Recruiting
120 enrolled
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Phase 2/3 Recruiting
120 enrolled
UmbrellaMAX
Phase 3 Recruiting
100 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
DEL-LIVER
Phase 2 Recruiting
90 enrolled
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Phase 1 Recruiting
220 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
TroFuse-021
Phase 3 Recruiting
900 enrolled
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Phase 1 Recruiting
265 enrolled
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Phase 2 Recruiting
75 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Phase 2 Recruiting
140 enrolled
MK-3475-C66
Phase 3 Recruiting
100 enrolled
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Phase 3 Recruiting
255 enrolled
Kirros
Phase 2 Recruiting
30 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
TRIBE-C
Phase 3 Recruiting
528 enrolled
DO-01
Phase 3 Recruiting
582 enrolled
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2 Recruiting
20 enrolled
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Phase 2 Recruiting
40 enrolled
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3 Recruiting
560 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
FOBEAR
Phase 3 Recruiting
582 enrolled
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Phase 1 Recruiting
542 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
RAINFOL-04
Phase 3 Recruiting
528 enrolled
HARMONi-GI3
Phase 3 Recruiting
600 enrolled
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 Recruiting
37 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase 3 Recruiting
408 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1 Recruiting
19 enrolled
MORPHEUS-LIVER
Phase 1/2 Recruiting
518 enrolled
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Phase 1/2 Recruiting
366 enrolled